Rani Therapeutics Holdings (RANI) EBIT Margin (2020 - 2026)

Rani Therapeutics Holdings (RANI) posted EBIT Margin of 516.86% for Q2 2026, down 5.86% on a QoQ basis from 488.23% in Q1 2026.

Analysis

Rani Therapeutics Holdings (RANI) EBIT Margin (2020 - 2026) Analysis & Trends

Rani Therapeutics Holdings has reported EBIT Margin for 5 years, with the latest figure at 516.86% in Q2 2026.

On a quarterly basis, EBIT Margin changed N/A year-over-year to 516.86% in Q2 2026; TTM through Jun 2026 was 675.8%, a 343045.0% increase from a year earlier, with the FY2025 full-year figure at 2345.99%, up 284020.0% from the prior year.
EBIT Margin was 516.86% for Q2 2026 at Rani Therapeutics Holdings, down from 488.23% in the prior quarter.
The five-year high for EBIT Margin was 488.23% in Q1 2026, with the low at 6984.3% in Q1 2025.
Average EBIT Margin over 3 years is 2005.73%, with a median of 584.19% recorded in 2025.
The sharpest annual moves came in 2025 and 2026: EBIT Margin surged 87087 bps in 2025, then surged 649607 bps in 2026.
Over 3 years, EBIT Margin stood at 1455.06% in 2024, then soared by 60 bps to 584.19% in 2025, then climbed by 12 bps to 516.86% in 2026.
The last three EBIT Margin figures came in at 516.86% (Q2 2026), 488.23% (Q1 2026), and 584.19% (Q4 2025), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Amgen	203.97 Bn	189.99 Bn	7.24 Bn	34.95%
2	Gilead Sciences	178.74 Bn	175.56 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	130.73 Bn	122.88 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	80.42 Bn	72.42 Bn	3.93 Bn	30.15%
5	Argenx Se	60.40 Bn	55.21 Bn	1.37 Bn	32.54%
6	Moderna	57.65 Bn	52.52 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	33.37 Bn	30.07 Bn	992.69 Mn	17.93%
8	Biogen	32.15 Bn	30.86 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	29.58 Bn	29.58 Bn	1.16 Mn	-25,380.93%
10	Rani Therapeutics Holdings	157.97 Mn	157.97 Mn	-	-516.86%

Historic Data

Download Data